All In Biotech

Drug Trial Radar · NCT04631016

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis (FRONTIER 4)

Last checked: Nov 20, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 137 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

137

Actual

Start

Dec 14, 2020

Primary completion

May 30, 2023

Study completion Nov 13, 2023

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult participants with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Chronic Bronchitis

Interventions

  • TozorakimabDrug

    Participants will receive SC injection of tozorakimab as stated in arm description.

  • PlaceboOther

    Participants will receive SC injection of placebo as stated in arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in ClinicTime frame: Baseline (Day -35 to Day -28) through Week 12

Locations

90 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site

    Sheffield, Alabama

  • Research Site

    Newport Beach, California

  • Research Site

    Newark, Delaware

  • Research Site

    Kissimmee, Florida

  • Research Site

    Ormond Beach, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Lakeside Park, Kentucky

  • Research Site

    White Marsh, Maryland

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    New Bern, North Carolina

  • Research Site

    Columbus, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    North Charleston, South Carolina

  • Research Site

    Spartanburg, South Carolina

  • Research Site

    Boerne, Texas

  • Research Site

    Nedlands, Australia

  • Research Site

    South Brisbane, Australia

  • Research Site

    Spearwood, Australia

  • Research Site

    Tarragindi, Australia

  • Research Site

    St. John's, Newfoundland and Labrador, Canada

  • Research Site

    Ajax, Ontario, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Sherbrooke, Quebec, Canada

  • Research Site

    Trois-Rivières, Quebec, Canada

  • Research Site

    Brno, Czechia

  • Research Site

    Olomouc, Czechia

  • Research Site

    Písek, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Rokycany, Czechia

  • Research Site

    Aalborg, Denmark

  • Research Site

    Hvidovre, Denmark

  • Research Site

    København NV, Denmark

  • Research Site

    Næstved, Denmark

  • Research Site

    Odense C, Denmark

  • Research Site

    Bamberg, Germany

  • Research Site

    Berlin, Germany

  • Research Site

    Berlin, Germany

  • Research Site

    Darmstadt, Germany

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.